LANTERN PHARMA INC

Company Overview

Lantern Pharma (LTRN) is an AI‑driven oncology biopharma that uses its RADR® machine‑learning platform to rescue and develop small‑molecule cancer therapies and an ADC program. Its clinical portfolio includes three lead small‑molecule candidates (LP‑300 in a Phase 2 Harmonic™ trial, LP‑184 and LP‑284 in Phase 1A) and a CNS subsidiary (Starlight) pursuing brain‑cancer indications and orphan designations. The company is development‑stage and largely outsourced (CROs/CMOs), employs ~24 people, is pre‑revenue, and runs trials across the U.S., Asia and Australia. As of mid‑2025 Lantern reported roughly $15.9M in cash and marketable securities, management expects runway into June 2026 absent new financings, and it has an ATM capacity (~$15.53M) to raise equity.

Executive Compensation Practices

Compensation at Lantern is likely driven by clinical and technical milestones (enrollment pace, IND/NDA progress, trial readouts), platform development (RADR® performance and IP growth) and capital‑raising objectives, which is typical for small biotech firms. Given the pre‑revenue status and limited cash runway, pay packages are likely equity‑heavy (stock options/RSUs and milestone‑based vesting) with modest base salaries to conserve cash; management has flagged that valuation of stock‑based awards materially affects reported expenses. Short‑term incentives or milestone bonuses tied to successful dosing, orphan designations, partnerships/licensing, or out‑licensing transactions are probable levers to align executives with value‑creating events. Because R&D accruals and option valuation assumptions (Black‑Scholes inputs) materially affect reported results, compensation committees may use equity timing and structure to balance GAAP expense impacts and retention needs.

Insider Trading Considerations

Insiders at Lantern are likely concentrated holders of equity and may need to monetize positions for tax or liquidity reasons, increasing the probability of reported Form 4 activity after option exercises, financings or public offerings. Expect insider trades to cluster around equity raises (including the July 2025 ATM program), post‑earnings windows, and after major clinical or regulatory news (trial enrollment milestones, IND/approval status, partnership announcements)—all of which are material events for a development‑stage biotech. Standard safeguards (board‑approved trading policies, blackout periods ahead of clinical readouts and earnings, and 10b5‑1 plans) are especially important here because cross‑border trial activities and staggered enrollment can create asynchronous material nonpublic information. For traders, watch Form 4 filings and aligning insider sale timing with company financing disclosures, since reliance on equity financing increases dilution risk and may influence the timing and scale of insider sales.